# Addex Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/addex-pharma

- Industry: Pharmaceuticals
- Headquarters: Geneva, Switzerland
- Website: www.addextherapeutics.com
- Total disclosed funding: $82M
- Latest round: Series C (Sep 19, 2006)
- Investors on record: 12

## About

Based in Switzerland, Addex Pharma SA focuses on the development of innovative small molecule drugs, particularly allosteric modulators for treating neurological disorders.Addex Pharma SA, founded in 2002 and headquartered in Geneva, Switzerland, specializes in drug development aimed at neurological disorders. The company has undergone several funding rounds, with the latest being a Private Placement/Follow-on raising CHF 0.85 mn on December 20, 2019, from Indivior. Over its history, Addex has completed 40 deals and has raised a total of CHF 0.85 mn. The company was involved in an IPO in May 2007, raising CHF 136.90 mn, and has seen various investment rounds since, including significant funding from Indivior.Addex Therapeutics specializes in developing orally available small molecule drugs, with a focus on allosteric modulators for neurological disorders. These modulators enhance or inhibit neurotransmitter effects, presenting a novel approach to conditions such as anxiety, depression, and Parkinson's disease. The company's products target specific neurological pathways to improve patient outcomes and are sought by pharmaceutical firms and research institutions primarily in North America and Europe.For the most recent fiscal year 2022, Addex Therapeutics reported revenue of CHF 1,490,945.50. However, the company reported an EBITDA of -CHF 21,169,794.80, indicating ongoing investment in research and development.Addex Pharma SA aims to expand its product offerings with new allosteric modulators tailored for neurological conditions. The company plans to leverage funding from recent rounds, including CHF 850,000 raised in August 2022, specifically for researching GABA positive allosteric modulators. Furthermore, Addex is targeting expansion into both North American and European markets by 2025, focusing on collaborations with larger pharmaceutical companies to enhance the development and commercialization of its proprietary technologies.

## Funding rounds

- Series C, Sep 19, 2006, $32M — Index Ventures, Sofinnova Partners, TVM Capital Life Science, PolyTechnos Venture-Partners, SR One, Renaissance Foundation & Management, SG Growth Capital, Roche Venture Fund, Varuma
- Series B, May 17, 2004, $40M — Index Ventures, Sofinnova Partners, TVM Capital Life Science, PolyTechnos Venture-Partners, Renaissance Foundation & Management, SG Growth Capital, Fulcrum Pharma, Initiative Capital Romandie
- Series A, Jul 11, 2002, $9.9M — Index Ventures, Sofinnova Partners, TVM Capital Life Science, BCV Initiative Capital

## Investors

- Index Ventures (https://capitalatlas.ai/funds/index-ventures) — Series A, Series B, Series C
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A, Series B, Series C
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series A, Series B, Series C
- BCV Initiative Capital — Series A
- PolyTechnos Venture-Partners (https://capitalatlas.ai/funds/polytechnos-venture-partners) — Series B, Series C
- Renaissance Foundation & Management (https://capitalatlas.ai/funds/renaissance-foundation-management) — Series B, Series C
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series B, Series C
- Fulcrum Pharma — Series B
- Initiative Capital Romandie — Series B
- SR One (https://capitalatlas.ai/funds/sr-one) — Series C
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series C
- Varuma — Series C